<img src="https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7?size=2" nborder="0" align="left" hspace="5" vspace="5" title="22157.jpg" alt="Company Logo"/>Dublin, Aug. 19, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- The <a href="https://www.researchandmarkets.com/reports/6260995/sports-medicine-biologics-market-share?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=g8l6vh&amp;utm_campaign=2329445+-+Sports+Medicine+Biologics+Market+Research+Report+2026-2031%3a+Demand+for+Faster+Recovery+and+Reduced+Downtime+Drives+Market+Growth&amp;utm_exec=jocamsai" rel="nofollow" target="_blank" title="Sports Medicine Biologics - Market Share Analysis, Industry Trends &amp; Statistics, Growth Forecasts (2026-2031)">"Sports Medicine Biologics - Market Share Analysis, Industry Trends &amp; Statistics, Growth Forecasts (2026-2031)"</a> has been added to ResearchAndMarkets.com's offering. The global sports medicine biologics market was valued at USD 1.79 billion in 2025 and is projected to increase from USD 1.88 billion in 2026 to USD 2.43 billion by 2031. The market is forecast to expand at a compound annual growth rate of 5.25% during 2026-2031. Market growth is supported by the rising incidence of sports injuries, musculoskeletal disorders and degenerative joint conditions, alongside increasing demand for treatments designed to improve recovery and delay or avoid major surgery. The report analyzes the market by product type, application, end user and geography, with forecasts provided in USD. Rising Injury Burden and Repeat Procedure Demand The global prevalence of musculoskeletal disorders increased by 71% between 1990 and 2024, while osteoarthritis is expected to remain a major contributor to disease burden through 2050. In the United States, annual sports-related injuries among adults aged 65 and older are projected to reach 111,225 by 2040, representing a 119% increase from 2024. Over the same period, the supply of sports medicine physicians is forecast to grow by only 19.7%. This widening supply-demand gap is encouraging the adoption of office-based biologic procedures and outpatient orthopedic care. Osteoarthritis affects approximately 32.5 million adults in the United States and generates an estimated annual economic burden of USD 137 billion, strengthening demand for biologic interventions before joint replacement. FDA tissue-handling and quality requirements under 21 CFR Part 1271 also support established suppliers with compliant manufacturing and processing capabilities. Demand for Faster Recovery and Reduced Downtime Professional sports organizations, rehabilitation programs and orthopedic practices are increasingly incorporating autologous biologics into treatment pathways. Faster recovery and return to activity carry significant clinical, competitive and financial value. Although NFL data for the 2025 regular season indicated a 25% decline in anterior cruciate ligament tears, demand for cartilage repair remained resilient because of chronic degenerative and osteochondral conditions. Clinical evidence is also supporting greater treatment standardization. A 2025 network meta-analysis covering 23 randomized controlled trials found that leukocyte-poor platelet-rich plasma with high platelet concentration produced strong WOMAC function and stiffness outcomes at 12 to 18 months. Reimbursement and Regulatory Constraints Limited insurance coverage remains a significant obstacle to sports medicine biologics market growth, particularly for platelet-rich plasma procedures. Major payers continue to classify PRP as investigational across several orthopedic indications, including knee osteoarthritis, Achilles tendinopathy, lateral epicondylitis and rotator cuff repair augmentation. Variation in platelet concentration, leukocyte content, injection volume and activation methods contributes to inconsistent clinical outcomes and complicates reimbursement decisions. Regulatory scrutiny of cell-based products and human tissue therapies also increases development costs and may delay commercialization. Additional market factors include the expansion of arthroscopy-linked procedures and the continued shift toward ambulatory surgical centers. Product and Application Analysis Bone graft substitutes accounted for 28.58% of sports medicine biologics market revenue in 2025, making them the leading product category. Their position reflects widespread use in osteochondral lesion repair, bone void filling following ligament reconstruction and reinforcement at tendon-to-bone fixation sites. Kuros Biosciences reported that its MagnetOs platform had been used in 100,000 cumulative surgeries worldwide and generated USD 146.1 million in 2025 revenue, an increase of 71.7% year over year. Stem cell-based products are forecast to record the fastest product growth, with a CAGR of 6.20% through 2031. Expansion is being supported by regulatory progress in knee cartilage repair and osteoarthritis programs. In June 2026, MEDIPOST secured FDA agreement for a single pivotal Phase 3 study of CARTISTEM in the United States and Canada, supported by investment in cGMP manufacturing capacity. The report covers platelet-rich plasma products, bone graft substitutes, bone morphogenetic proteins, stem cell-based products, viscosupplementation products, amniotic and placental tissue products, hyaluronic acid injections and other biologics. Applications include the knee, shoulder, foot and ankle, hip and groin, elbow and wrist, and other anatomical areas. End users include hospitals, ambulatory surgical centers, specialty orthopedic clinics and sports medicine centers. Regional Market Outlook North America represented an estimated 40.30% of global revenue in 2025, making it the largest regional sports medicine biologics market. Extensive outpatient surgical infrastructure, high sports participation and established commercialization pathways support regional demand. However, reimbursement restrictions continue to limit the broader adoption of PRP and other biologic therapies. The United States leads the region, while Canada and Mexico offer additional opportunities as orthopedic infrastructure and payment pathways develop. Europe maintains substantial demand, led by Germany, the United Kingdom and France. Germany is an important adoption center for cartilage biologics used in larger chondral defects. EU Medical Device Regulation requirements, the European Medicines Agency's advanced therapy framework and separate oversight by the UK Medicines and Healthcare products Regulatory Agency increase compliance obligations for manufacturers. Asia-Pacific is forecast to be the fastest-growing regional market, registering a CAGR of 7.45% through 2031. Growth is driven by expanding private sports clinics, increasing orthopedic procedure volumes and supportive regenerative medicine pathways in markets such as Japan. South Korea also remains a significant development and export center for advanced biologic and point-of-care systems. The Middle East and Africa and South America currently account for smaller shares but offer long-term potential through private hospital investment and broader orthopedic capacity. Key Topics Covered 1 INTRODUCTION 1.1 Study Assumptions and Market Definition 1.2 Scope of the Study 2 RESEARCH METHODOLOGY 3 EXECUTIVE SUMMARY 4 MARKET LANDSCAPE 4.1 Market Overview 4.2 Market Drivers 4.2.1 Rising Sports Injury Burden and Repeat Procedure Demand 4.2.2 Shift Toward Faster Recovery and Reduced Downtime 4.2.3 Expansion of Arthroscopy-Linked Biologic Adjacent Procedures 4.2.4 Surge in Outpatient And ASC-Based Orthopedic Care 4.2.5 Growth In Surgeon-Preferred Point-of-Care Biologic Preparation Systems 4.3 Market Restraints 4.3.1 Payer Reluctance Toward Nonstandardized Biologic Therapies 4.3.2 Regulatory Scrutiny on Cell-Based and Human Tissue Products 4.3.3 Inconsistent Clinical Evidence Across Product Classes 4.4 Supply/Value Chain Analysis 4.5 Regulatory Landscape 4.6 Technological Outlook 4.7 Porter's Five Forces Analysis 4.7.1 Bargaining Power Of Suppliers 4.7.2 Bargaining Power Of Buyers 4.7.3 Threat Of New Entrants 4.7.4 Threat Of Substitutes 4.7.5 Industry Rivalry 5 MARKET SIZE AND GROWTH FORECASTS (VALUE, USD) 5.1 By Product Type 5.1.1 Platelet-Rich Plasma Products 5.1.2 Bone Graft Substitutes 5.1.3 Bone Morphogenetic Proteins 5.1.4 Stem Cell-Based Products 5.1.5 Viscosupplementation Products 5.1.6 Amniotic And Placental Tissue Products 5.1.7 Hyaluronic Acid Injections 5.1.8 Others 5.2 By Application 5.2.1 Knee 5.2.2 Shoulder 5.2.3 Foot And Ankle 5.2.4 Hip And Groin 5.2.5 Elbow And Wrist 5.2.6 Others 5.3 By End User 5.3.1 Hospitals 5.3.2 Ambulatory Surgical Centers 5.3.3 Specialty Orthopedic Clinics 5.3.4 Sports Medicine Centers 5.3.5 Others 5.4 By Geography 5.4.1 North America 5.4.1.1 United States 5.4.1.2 Canada 5.4.1.3 Mexico 5.4.2 Europe 5.4.2.1 Germany 5.4.2.2 United Kingdom 5.4.2.3 France 5.4.2.4 Italy 5.4.2.5 Spain 5.4.2.6 Rest of Europe 5.4.3 Asia-Pacific 5.4.3.1 China 5.4.3.2 India 5.4.3.3 Japan 5.4.3.4 Australia 5.4.3.5 South Korea 5.4.3.6 Rest of Asia-Pacific 5.4.4 Middle East and Africa 5.4.4.1 GCC 5.4.4.2 South Africa 5.4.4.3 Rest of Middle East and Africa 5.4.5 South America 5.4.5.1 Brazil 5.4.5.2 Argentina 5.4.5.3 Rest of South America 6 COMPETITIVE LANDSCAPE 6.1 Market Concentration 6.2 Market Share Analysis 6.3 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products and Services, Recent Developments) 6.3.1 AlloSource 6.3.2 Anika Therapeutics, Inc. 6.3.3 Arthrex, Inc. 6.3.4 Bioventus Inc. 6.3.5 Breg, Inc. 6.3.6 CONMED Corporation 6.3.7 DJO, LLC 6.3.8 Enovis Corporation 6.3.9 Integra LifeSciences Holdings Corporation 6.3.10 Johnson &amp; Johnson 6.3.11 Kuros Biosciences AG 6.3.12 LifeNet Health, Inc. 6.3.13 Medtronic plc 6.3.14 MTF Biologics 6.3.15 Organogenesis Holdings Inc. 6.3.16 Orthofix Medical Inc. 6.3.17 Smith &amp; Nephew plc 6.3.18 Stryker Corporation 6.3.19 Vericel Corporation 6.3.20 Zimmer Biomet Holdings, Inc. 7 MARKET OPPORTUNITIES AND FUTURE OUTLOOK 7.1 White-Space and Unmet-Need Assessment For more information about this report visit <a href="https://www.researchandmarkets.com/reports/6260995/sports-medicine-biologics-market-share?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=g8l6vh&amp;utm_campaign=2329445+-+Sports+Medicine+Biologics+Market+Research+Report+2026-2031%3a+Demand+for+Faster+Recovery+and+Reduced+Downtime+Drives+Market+Growth&amp;utm_exec=jocamsai" rel="nofollow" target="_blank" title="">https://www.researchandmarkets.com/r/mihexm</a> About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. <pre>CONTACT: 
CONTACT: ResearchAndMarkets.com 
 Laura Wood,Senior Press Manager 
 press@researchandmarkets.com
 For E.S.T Office Hours Call 1-917-300-0470 
 For U.S./ CAN Toll Free Call 1-800-526-8630 
 For GMT Office Hours Call +353-1-416-8900 

</pre> <img alt="" src='https://ml.globenewswire.com/media/ZGZiYTBkN2YtOWNlMS00MjgwLThmNmEtNzhlZjViMGI1MGRjLTEwMjY3MzctMjAyNi0wOC0xOS1lbg==/tiny/Research-and-Markets.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Sports Medicine Biologics Market Research Report 2026-2031: Demand for Faster Recovery and Reduced Downtime Drives Market Growth

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn